Talipexole

Talipexole

Systematic (IUPAC) name
6-allyl-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[4,5-d]azepin-2-amine
Clinical data
Trade names	Domin
AHFS/Drugs.com	International Drug Names
Legal status	℞ (Prescription only)
Routes of administration	Oral
Identifiers
CAS Number	36085-73-1
ATC code	None
PubChem	CID 5374
IUPHAR/BPS	5442
ChemSpider	5181
UNII	7AM2J46Z1Y
ChEMBL	CHEMBL1289023
Synonyms	Alefexole
Chemical data
Formula	C10H15N3S
Molar mass	209.31 g/mol
SMILES n1c2c(sc1N)CCN(CC2)C\C=C C=CCN1CCC2=C(CC1)SC(=N2)N
InChI InChI=1S/C10H15N3S/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8/h2H,1,3-7H2,(H2,11,12) Key:DHSSDEDRBUKTQY-UHFFFAOYSA-N
(what is this?)  (verify)

Talipexole (B-HT920, Domnin) is a dopamine agonist that is marketed as a treatment for Parkinson's Disease in Japan by Boehringer Ingelheim; it was introduced in 1996.^[1] As of December 2014 it was not approved for marketing in the US nor in Europe.^[2]

Talipexole is a D₂ dopamine receptor agonist and interacts both pre- and post-synaptic receptors. It also is an α2-adrenergic agonist.^[3]

The main side effects are drowsiness, dizziness, hallucinations and minor gastrointestinal complaints.^[3] In 2008 the Japanese Ministry of Health, Labour, and Welfare mandated that Boehringer add a warning to the label concerning the risk of sudden onset of sleep.^[4]:15

References

1. PharmaLetter 22 July 1996 First Launch In Japan For Talipexole
2. EvaluatePharma Database. Page accessed 9 December 2014
3. Benkert O, et al. Dopamine agonists in schizophrenia: a review. Eur Neuropsychopharmacol. 1995;5 Suppl:43-53. PMID 8775758
4. Japanese Ministry of Health, Labour and Welfare March 2008 Pharmaceuticals and Medical Devices Safety Information No. 245